Lupin
- Revenue₹149.3 BFY, 2021
- Market Capitalization₹293.8 B2022-05-26
OverviewSuggest Edit
Lupin is a USD 2.06 billion innovation led transnational pharmaceutical major producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 120,600 million (USD 2.06 billion) and Rs. 18,364 million (USD 393 million) respectively.
| Type | Public | |
| Founded | 1968 | |
| HQ | Mumbai, IN | Map |
| Website | lupin.com | |
| Employee Ratings |
Recent NewsAll News
- Global Intestinal Pseudo Obstruction Treatment Market Report 2022-2027 Featuring Pfizer, Cipla, GlaxoSmithKline, Teva., Eli Lilly and Co, Novartis, J&J, Dr. Reddy's Lab, F. Hoffmann-La Roche, Lupin
- Brokerages Cut Estimates For Lupin On U.S. Price Erosion, Cost Inflation
- Lupin Q4 Review - Growth Contingent On Niche Launches, Cost Optimisation: Motilal Oswal
- After Surprise Loss, Lupin Expects Much-Better Earnings In Second Half Of FY23
Key People/Management at Lupin
Manju D Gupta
Kamal K Sharma
Richard Zahn
K U Mada
Dileep C Choksi
Alan Butcher
Lupin Office Locations
Lupin Financials and Metrics
Lupin Revenue
| INR | |
|---|---|
Revenue (Q3, 2022) | 40.9b |
Gross profit (Q3, 2022) | 25.0b |
Net income (Q3, 2022) | 5.5b |
EBITDA (Q3, 2022) | 4.0b |
EBIT (Q3, 2022) | 2.0b |
Market capitalization (26-May-2022) | 293.8b |
Closing stock price (26-May-2022) | 600.5 |
EV | 293.8b |
| INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 155.5b | 163.7b | 166.0b | 149.3b |
Cost of goods sold | (57.5b) | (63.1b) | (59.7b) | (59.2b) |
Gross profit | 100.5b | 104.1b | 108.6b | 92.9b |
R&D expense | (18.4b) | (15.8b) | (15.1b) | (14.3b) |
| INR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 37.7b | 38.9b | 43.8b | 43.6b | 43.0b | 37.2b | 34.7b | 37.8b | 39.2b | 42.4b | 40.0b | 40.9b |
Cost of goods sold | (14.4b) | (13.9b) | (16.0b) | (15.5b) | (15.3b) | (13.6b) | (12.9b) | (13.8b) | (13.7b) | (15.3b) | (16.3b) | (16.9b) |
Gross profit | 26.0b | 27.9b | 29.5b | 29.4b | 29.6b | 25.0b | 22.8b | 24.8b | 26.6b | 27.7b | 25.3b | 25.0b |
R&D expense | (3.8b) | (3.8b) | (425.7m) | (3.8b) | 3.8b |
| INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 14.1b | 9.9b | 24.5b | 17.4b |
Accounts Receivable | 51.9b | 51.5b | 54.5b | 44.7b |
Prepaid Expenses | 5.1b | 5.2b | 6.8b | 2.9b |
Inventories | 36.6b | 38.4b | 34.6b | 40.9b |
| INR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 10.9b | 11.6b | 13.2b | 12.8b | ||||||||
Accounts Receivable | 52.0b | 49.2b | 48.0b | 43.1b | ||||||||
Prepaid Expenses | 2.0b | 123.9m | ||||||||||
Inventories | 38.5b | 41.1b | 40.2b | 44.7b |
| INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | 5.5b | 15.2b | 7.6b | 16.8b |
Depreciation and Amortization | 10.9b | 10.9b | 11.6b | 8.9b |
Inventories | 172.7m | (2.9b) | (4.8b) | (6.6b) |
Accounts Payable | (305.8m) | (1.6b) | 5.6b | (3.7b) |
| INR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.4b | 6.3b | (14.5b) | |||||||||
Depreciation and Amortization | 6.4b | 4.3b | 11.3b | |||||||||
Inventories | (2.6b) | (5.9b) | (3.9b) | |||||||||
Accounts Payable | 1.6b | (206.0m) | 3.4b |
| INR | FY, 2018 |
|---|---|
Revenue/Employee | 9.3m |
Lupin Revenue Breakdown
Lupin revenue breakdown by business segment: 100.0% from PHARMACEUTICAL
Lupin Cybersecurity Score
Lupin Environment, Social & Governance (ESG) Ratings
Lupin Online and Social Media Presence
38 Twitter followers
Lupin has 38 Twitter Followers. The number of followers has increased 3.8% quarter over quarter
Lupin's Trends
Lupin News and Updates
Global Intestinal Pseudo Obstruction Treatment Market Report 2022-2027 Featuring Pfizer, Cipla, GlaxoSmithKline, Teva., Eli Lilly and Co, Novartis, J&J, Dr. Reddy's Lab, F. Hoffmann-La Roche, Lupin
Brokerages Cut Estimates For Lupin On U.S. Price Erosion, Cost Inflation
Lupin Q4 Review - Growth Contingent On Niche Launches, Cost Optimisation: Motilal Oswal
After Surprise Loss, Lupin Expects Much-Better Earnings In Second Half Of FY23
Share Market Live: Sensex, Nifty Set To Fall; ITC, BPCL, Lupin, Adani Enterprises, IndiGo In Focus
Stocks To Watch Today: BPCL, Dr Reddy's, IndiGo, ITC, Lupin, Ruchi Soya
Lupin Blogs
Lupin Frequently Asked Questions
When was Lupin founded?
Lupin was founded in 1968.
Who are Lupin key executives?
Lupin's key executives are Manju D Gupta, Kamal K Sharma and Richard Zahn.
How many employees does Lupin have?
Lupin has 18,573 employees.
What is Lupin revenue?
Latest Lupin annual revenue is ₹149.3 b.
What is Lupin revenue per employee?
Latest Lupin revenue per employee is ₹8 m.
Who are Lupin competitors?
Competitors of Lupin include Mito BioPharma, Sciwind and Tetra Therapeutics.
Where is Lupin headquarters?
Lupin headquarters is located at Laxmi Towers BKC Road, Mumbai.
Where are Lupin offices?
Lupin has offices in Mumbai, Ankleshwar, Aurangabad, Bhopal and in 11 other locations.
How many offices does Lupin have?
Lupin has 18 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies